<DOC>
	<DOCNO>NCT01802567</DOCNO>
	<brief_summary>The purpose study test feasibility ( ability do ) experimental technology determine tumor 's molecular makeup ( gene expression profile ) mutation . This technology call `` Pediatric Gene Analysis Platform '' include genomic report ( gene expression profile ) DNA Mutation Panel Report use discover new way understand cancer potentially predict best treatment patient cancer future .</brief_summary>
	<brief_title>Molecular-Guided Therapy Relapsed Refractory Childhood Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>Subjects must histologically prove neuroblastoma , brain tumor , rare tumor confirmation refractory recurrent disease histologic confirmation diagnosis time recurrence/progression Subjects must age &gt; 12 month enrollment . Subjects must age ≤ 21 year initial diagnosis . Subjects must measurable disease demonstrate residual abnormal tissue primary metastatic site measure 1 cm dimension standardize imaging ( CT MRI ) ; tumor must accessible biopsy . Patients bone marrow disease expect &gt; 75 % tumor eligible enroll . Current disease state must one currently know curative therapy Lansky Karnofsky Score must 50 Subjects without bone marrow metastases must ANC &gt; 750/μl Adequate liver function must demonstrate , define : 1 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) age AND 2 . SGPT ( ALT ) &lt; 10 x upper limit normal ( ULN ) age A negative serum pregnancy test require female participant child bear potential ( ≥13 year age onset menses ) Both male female postpubertal study subject need agree use one effective birth control method treatment six month treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . If one use , contraceptive foam condom recommend . Informed Consent : All subject and/or legal guardian must sign informed write consent . Assent , appropriate , obtain accord institutional guideline . Voluntary consent optional biology study include . Subjects receive cytotoxic chemotherapy within last 7 day prior enrollment 14 day prior study treatment start date . Subjects receive radiotherapy primary sample site within last 14 day ( radiation may include treatment decision biopsy ) . Subjects receive antitumor therapy disease investigational drug concurrently Subjects serious infection lifethreatening illness ( unrelated tumor ) &gt; Grade 2 ( NCI CTCAE V4.0 ) , active , serious infection require parenteral antibiotic therapy . Subjects medical condition , include malabsorption syndrome , mental illness substance abuse , deem Investigator likely interfere interpretation result would interfere subject 's ability sign legal guardian 's ability sign inform consent , subject 's ability cooperate participate study</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>